Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 386, Issue 17, Pages 1668-1669Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMc2119768
Keywords
-
Categories
Ask authors/readers for more resources
The study suggests that tumors that become resistant to PD-1 and LAG-3 therapy may also develop cross-resistance to ipilimumab.
Ipilimumab after Anti-PD-1 and Anti-LAG-3 Therapy Data were pooled from 36 patients who received the anti-CTLA-4 antibody ipilimumab after metastatic melanoma progression during therapy with nivolumab (anti-PD-1) plus relatlimab (anti-LAG-3) to assess whether immunotherapies that target distinct checkpoints have different mechanisms of action. The findings suggest that cross-resistance emerges when tumors progress with immune checkpoint inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available